-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Sector Analysis
NewCell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...
-
Company Insights
Innovation and Patenting activity of Option Care Health Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Option Care Health Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewUnited Kingdom (UK) Travel Insurance Distribution Dynamics by Channels and Future Market, 2023 Update
United Kingdom (UK) Travel Insurance Market Report Overview The UK travel insurance market research report offers insights into consumer purchasing decisions within the travel insurance scenario and discusses their influence on the market over the next few years. In 2023, more than 24% of travel insurance purchases were via PCWs, which suggests that consumers want more details from their providers about their coverage levels, policy options, and premium pricing. Additionally, single-trip policies maintained their popularity during the year Leading Distribution...
-
Product Insights
NewLikelihood of Approval Analysis for Obstructive Pulmonary Disease
Overview How likely is it that the drugs in Obstructive Pulmonary Disease will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Obstructive Pulmonary Disease Overview Chronic obstructive pulmonary disease (COPD) is a...
-
Product Insights
NewLikelihood of Approval Analysis for Osteosarcoma
Overview How likely is it that the drugs in Osteosarcoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Osteosarcoma Overview Osteosarcoma is a type of bone cancer that develops in the...
-
Product Insights
NewLikelihood of Approval Analysis for Ocular Inflammation
Overview How likely is it that the drugs in Ocular Inflammation will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocular Inflammation Overview Ocular inflammation is an eye inflammation that include choroiditis,...
-
Product Insights
NewLikelihood of Approval Analysis for Sphingolipidoses
Overview How likely is it that the drugs in Sphingolipidoses will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sphingolipidoses Overview Sphingolipidoses are a heterogeneous group of inherited disorders of lysosomal storage...
-
Product Insights
NewLikelihood of Approval Analysis for Benign Tumor
Overview How likely is it that the drugs in Benign Tumor will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Benign Tumor Overview A benign Tumor is also known as non-cancerous. It...